<DOC>
	<DOC>NCT02503293</DOC>
	<brief_summary>A randomised, cross-over study to compare quality of life and satisfaction in primary immunodeficient patients treated with subcutaneous injections of Gammanorm® 165 mg/mL administered with two different delivery devices: injections using pump or rapid push.</brief_summary>
	<brief_title>A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<criteria>Inclusion criteria: Adult patients (≥ 18 years). Presenting with primary immunodeficiency. Having received subcutaneous injections of immunoglobulin at home using an automatic pump or syringe for at least 1 month at the time of inclusion. For whom the investigator decides to maintain immunoglobulin replacement therapy with subcutaneous injections of Gammanorm® 165 mg/mL at home. Freely given written informed consent from patient. Women of childbearing potential must have a negative result on a pregnancy test (human chorionic gonadotropine [HCG]based assay) and need to practice contraception using a method of proven reliability for the duration of the study. • Participating in another interventional clinical study and receiving investigational medicinal product within three months before study entry.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>